XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 8,099 $ 21,666
Accounts and other receivables 5,000 5,000
Prepaid and other current assets 915 1,540
Total current assets 14,014 28,206
Other assets, noncurrent 168 168
Right-of-use assets 17 66
Property and equipment, net 1 4
Total assets 18,750 28,444
Current liabilities:    
Accounts payable 16 194
Accrued compensation 1,085 2,582
Other accrued liabilities 743 1,452
Dividends payable   7,558
CVR derivative liability 5,000 5,000
Operating lease liability   38
Total current liabilities 6,844 16,824
CVR derivative liability, noncurrent 4,550  
Total liabilities 11,394 16,824
Commitments and Contingencies (Note 9)
Stockholders’ deficit:    
Common stock, $0.001 par value, 100,000,000 shares authorized; 37,759,825 and 37,756,574 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 37 37
Additional paid-in capital 384,686 389,210
Accumulated deficit (410,676) (410,936)
Total stockholders’ deficit (25,953) (21,689)
Total liabilities, redeemable convertible preferred stock and stockholders’ deficit 18,750 28,444
Redeemable Convertible Preferred Stock    
Current liabilities:    
Redeemable convertible preferred stock, $0.001 par value, 123,418 shares authorized; 12,340 shares issued and outstanding at March 31, 2023 and December 31, 2022 33,309 $ 33,309
GC Biopharma Corp    
Current assets:    
Long-term receivable from GCBP $ 4,550